» Articles » PMID: 21047422

The Prognostic Value of Tumor Markers Doubling Times in Medullary Thyroid Carcinoma - Preliminary Report

Overview
Journal Thyroid Res
Specialty Endocrinology
Date 2010 Nov 5
PMID 21047422
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Calcitonin (Ct) and carcinoembrional antigen (CEA) are widely used as tumor markers for the post-operative follow-up of patients with medullary thyroid carcinoma (MTC).In patients with elevated serum Ct and CEA their dynamics can be described by calculating the doubling time (DT) - the time, they need to double the serum concentration. Previous reports concluded that the Ct and CEA DT have prognostic value in MTC patients.

Patients And Methods: We retrospectively analyzed data of 70 MTC patients with elevated serum Ct or CEA. In total, doubling times were calculated and the DT of the less favorable marker was used to stratify the patients into the low- and high-risk group with the cut-off value of 2 years. The survival analysis was performed using Cox proportional hazard method.

Results: The doubling time < = 2 years of the less-favorable marker had significant prognostic impact for recurrence-free survival, HR = 2.61 (1.43-4.71) and overall survival, HR = 8.99 (3.51-23.04).

Conclusions: The calcitonin and carcinembrional antigen doubling times of less than two years are negative prognostic factors for MTC recurrence-free and total survival in patients with persistent or recurrent disease. They may be used as predictive factors for more intensive search of disease localization in asymptomatic hypercalcitoninemia and for therapy choice in symptomatic disease.

Citing Articles

Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update.

Liu S, Zhao H, Li X Cancer Manag Res. 2024; 16:299-310.

PMID: 38617188 PMC: 11011642. DOI: 10.2147/CMAR.S440477.


Molecular Imaging and Theragnostics of Thyroid Cancers.

Giovanella L, Deandreis D, Vrachimis A, Campenni A, Petranovic Ovcaricek P Cancers (Basel). 2022; 14(5).

PMID: 35267580 PMC: 8909041. DOI: 10.3390/cancers14051272.


Current status of the prognostic molecular markers in medullary thyroid carcinoma.

Oczko-Wojciechowska M, Czarniecka A, Gawlik T, Jarzab B, Krajewska J Endocr Connect. 2020; 9(12):R251-R263.

PMID: 33112827 PMC: 7774764. DOI: 10.1530/EC-20-0374.


Calcitonin Screening in Nodular Thyroid Disease: Is There a Definitive Answer?.

Silvestre C, Sampaio Matias J, Proenca H, Bugalho M Eur Thyroid J. 2019; 8(2):79-82.

PMID: 31192146 PMC: 6514514. DOI: 10.1159/000494834.


Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer - An Evolving Paradigm.

Jarzab B, Krajewska J Eur Endocrinol. 2018; 10(2):145-150.

PMID: 29872479 PMC: 5983084. DOI: 10.17925/EE.2014.10.02.145.


References
1.
Meijer J, le Cessie S, van den Hout W, Kievit J, Schoones J, Romijn J . Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf). 2009; 72(4):534-42. DOI: 10.1111/j.1365-2265.2009.03666.x. View

2.
Giraudet A, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F . Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008; 158(2):239-46. DOI: 10.1530/EJE-07-0667. View

3.
Barbet J, Campion L, Kraeber-Bodere F, Chatal J . Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005; 90(11):6077-84. DOI: 10.1210/jc.2005-0044. View

4.
Kloos R, Eng C, Evans D, Francis G, Gagel R, Gharib H . Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009; 19(6):565-612. DOI: 10.1089/thy.2008.0403. View

5.
Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K . Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg. 1984; 199(4):461-6. PMC: 1353366. DOI: 10.1097/00000658-198404000-00014. View